Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients
Status:
Completed
Trial end date:
2021-05-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a higher dose of low molecular weight
heparin (enoxaparin 40 mg b.i.d.) is superior than the standard prophylaxis dose (enoxaparin
40 mg o.d.) in reducing thromboembolic events in COVID-19 patients.